|Budget Amount *help
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|Outline of Final Research Achievements
Although chemotherapy using docetaxel is conducted for castration-resistant prostate cancer (CRPC) after androgen-deprivation therapy, CRPC become resistant for docetaxel again. We hypothesized that the mechanism is related with tumor microenvironment. Then we co-cultured androgen-independent prostate cancer PC-3 with cancer-associated fibroblast (CAF) and investigated whether CAF affect docetaxel-sensitivity. However, CAF did not affect DOC-sensitivity.
Next, we hypothesized that CAF derived from CRPC is different from CAF from androgen-naive prostate cancer. Then we made gene expression profiles from CAF derived from CRPC and CAF from androgen-naive prostate cancer. We identified several differentially expressed genes. Now we are confirming whether these genes are related with CRPC progression.